NeuroLogica Receives US FDA Clearance for AI-based Auto Lung Nodule Detection Tool
Samsung NeuroLogica announced it has received US FDA clearance for its Auto Lung Nodule Detection (ALND) tool. The offering provides an on-device, computer-assisted detection (CADe) solution for detecting pulmonary nodules from 10 to 30mm in size through an artificial intelligence (AI) algorithm. It is designed to aid the physician in reviewing PA chest radiographs of adults and is part of S-Station, an operation software installed on Samsung Digital X-ray Imaging systems.
“This FDA clearance is a huge milestone for Samsung and is the result of our tireless work to design diagnostic solutions that empower providers to deliver patients the absolute best care possible,” said David Legg, Vice President of Digital Radiography and Ultrasound at Samsung NeuroLogica. “The fact that it delivers clinically reliable results means clinicians can present it to patients with the utmost confidence, and for that we’re very proud.”
ALND aids the reader's diagnosis by indicating the location of suspected lung nodules on chest X-ray images (posteroanterior chest radiographs). The deep-learning technology has been clinically verified in multiple university hospitals and has been approved with a sensitivity of 80% or more. Investigators at these hospitals – Freiburg University Hospital, Freiburg, Germany; Massachusetts General Hospital, Boston, Massachusetts; Samsung Medical Center, Seoul, South Korea; and Severance Hospital, Seoul, South Korea – retrospectively identified 600 chest radiographs with lung cancer and 200 normal chest radiographs.
According to the company, the solution also has extensive external clinical validation that has been recognized by the radiological society for having been performed with ‘unprecedented’ diversity of images acquired under different conditions and demographics, while only producing a small number of false positives per image (0.15). ALND also provides an option (Autorun) to automatically perform nodule detection immediately after chest X-ray imaging, and providing PACS transmission options to suit the hospital environment, both which simplify a user’s workflow. The company says clinical evaluation results have demonstrated that all readers' nodule detection performances using ALND have increased with statistical significance.